[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mead Johnson Nutrition\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632424","extensively-hydrolyzed-formula-growth-monitioring-study-gms-100632424",false,"NCT07513506","Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)","GROWTH AND TOLERANCE OF A NEW INFANT FORMULA USING AN EXTENSIVELY HYDROLYZED CASEIN-BASED PROTEIN (eHCF)","Inclusion Criteria:\n\n* 10 to 14 days of age at randomization, inclusive (day of birth is considered Day 0)\n* Singleton birth\n* Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive\n* Birth weight of 2500 g to 4200 g, inclusive\n* Birth weight appropriate for gestational age (AGA, defined as birth weight-for-age between 10th and 90th percentile, inclusive)\n* Exclusively receiving infant formula for at least 24 hours prior to randomization\n* Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age\n* Signed informed consent obtained from parent or legal guardian for infant's participation in the study\n* Signed authorization obtained from parent or legal guardian to use and\u002For disclose Protected Health Information for the infant from birth through the length of the study period\n* Parent or legal guardian agrees not to enroll the infant in another interventional clinical study while participating in this study\n* Decentralized participant's parent\u002Fcaregiver or legal guardian has access to reliable internet and technology for remote visits.\n* Decentralized participant's parent\u002Fcaregiver or legal guardian anticipates having a second adult available for all remote visits.\n\nExclusion Criteria:\n\n* History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food by mouth, the normal growth and development of the infant, or the evaluation of the infant\n* Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization\n* First degree relative (if known) history of cow's milk protein intolerance or allergy\n* Maternal history with known adverse effects on the fetus and\u002For newborn infant in the opinion of the investigator, such as, but not limited to diabetes, smoking, active tuberculosis, perinatal infection, or substance abuse\n* Weight at Visit 1 is \\\u003C98% of birth weight \\[weight at Visit 1÷ birth weight) x 100\\\u003C 98%\\]\n* Infants whose parent, legal guardian, or first-degree relative is an employee of MJN\u002FReckitt or an affiliated vendor (e.g., CRO, laboratory, or data management provider) involved in the clinical trial, and who is directly or indirectly engaged in the design, conduct, oversight, or analysis of the study; has access to confidential study information; or holds supervisory authority over personnel involved in the study.",true,"ALL","10 Days","14 Days",{"count":21,"type":22},214,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a research study to compare an investigational infant formula against a currently marketed infant formula. An investigational infant formula is one that has never been approved by the United States Food and Drug Administration (FDA).\n\nThe purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively hydrolyzed cow milk protein infant formula compared to an extensively hydrolyzed cow milk protein infant formula that is currently available to buy. The study will also look at the growth of your baby, how many poops your baby has, what the poops are like (for example, soft or hard), how much study formula your baby drinks, how well your baby handles the study formula (such as spit-up, fussiness, gas, colic, or changes in sleep), and any health problems that might come up during the study.",[28],"Growth","NOT_YET_RECRUITING","2026-03-30",{"date":32,"type":33},"2026-04-07","ACTUAL",{"date":35,"type":22},"2026-04-03",{"date":37,"type":22},"2027-05-01",{"name":39,"class":40},"Mead Johnson Nutrition","INDUSTRY",12,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100631247","thai-baby-study-phase-1-100631247","NCT07498192","Thai Baby Study Phase 1","National Situational Analysis of Birth Mode and Infant Outcomes in Thailand","Inclusion Criteria:\n\n* Mother-infant dyads with delivery records available in the national health administrative database.\n* Deliveries occurring in public hospitals in Thailand during the study period.\n* Records containing information on mode of delivery and linked maternal and infant outcomes.\n\nExclusion Criteria:\n\n* Records with missing or invalid delivery mode information.\n* Records that cannot be reliably linked between mother and infant.","120 Years",{"count":51,"type":22},10300,"OBSERVATIONAL","The goal of this observational study is to examine national trends in mode of delivery and to assess associations between cesarean section and early-life health outcomes using routinely collected health data in Thailand. The study includes mother-infant dyads delivering in public hospitals across Thailand.\n\nThe main questions it aims to answer are:\n\nIs cesarean delivery associated with increased risk of adverse neonatal outcomes compared with vaginal delivery?\n\nIs cesarean delivery associated with differences in early-life healthcare utilization and breastfeeding outcomes during the first year of life?\n\nResearchers will compare infants born by cesarean section with infants born by vaginal delivery to evaluate differences in neonatal morbidity, healthcare utilization, and breastfeeding patterns.\n\nParticipants will not receive any intervention. The study involves secondary analysis of de-identified national health administrative and clinical data, including delivery records and linked maternal and infant health outcomes.",[55],"Outcome Assessment","2026-03-23",{"date":58,"type":33},"2026-03-27",{"date":60,"type":22},"2026-03-01",{"date":62,"type":22},"2026-12-31",{"name":39,"class":40},""]